New immune therapy shows promise for Tough-to-Treat lymphoma
NCT ID NCT06486051
First seen Jun 24, 2026 · Last updated Aug 07, 2026 · Updated 2 times
Summary
This phase 2 trial is testing a new CAR T-cell therapy called WZTL-002 for people with large B-cell lymphoma that has come back or not responded to standard treatment. The therapy uses a patient's own immune cells, modified to target and kill cancer cells. The study will measure how often the cancer disappears completely and how often serious brain side effects occur. 60 participants will receive the treatment and be followed for up to 2 years.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- WZTL-002 CAR T-cells (a type of immune cell therapy that targets CD19 on cancer cells)
- What this could lead to
- If successful, this could offer a new treatment option for people with large B-cell lymphoma that hasn't responded to standard therapy.
- What could go wrong
- This is a phase 2 trial with only 60 participants, so results may not apply to everyone. There are known risks of serious side effects like brain toxicity and cytokine release syndrome.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Auckland City Hospital
RECRUITINGAuckland, Auckland, 1023, New Zealand
Contact Email: •••••@•••••
-
Christchurch Hospital
RECRUITINGChristchurch, Christchurch Central, 8011, New Zealand
Contact Email: •••••@•••••
-
Wellington Hospital
RECRUITINGNewtown, Wellington Region, 6021, New Zealand
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Engineered immune cells take aim at Hard-to-Treat lymphomas
- Can a single shot build a cancer army inside the body?
- New combo therapy aims to boost remission in Hard-to-Treat lymphoma
- Engineered immune cells get a boost: new combo therapy targets Hard-to-Treat blood cancers
- Engineered immune cells take aim at Tough-to-Treat blood cancers
- New combo aims to boost lymphoma control in older patients